During an investor conference call after the Q1 report, CEO Richard Gonzalez said more than 21% of patients diagnosed with chronic lymphocytic leukemia (CLL) are now given the drug as first-line treatment, putting AbbVie in the No. 1 position in that market. The two outperformers helped cushion the blow of rapidly declining sales of Viekira Pak, AbbVie's hep C combo. Sales missed estimates in the U.S. last quarter and just keep falling as the drug fights for market share against Gilead Sciences' Harvoni. Viekira sales fell 36% to $263 million during the quarter.